Profile cover photo
Profile photo
Spring Bank Pharmaceuticals, Inc.
4 followers -
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharma company developing a novel class of therapeutics using our proprietary SMNH chemistry platform.
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharma company developing a novel class of therapeutics using our proprietary SMNH chemistry platform.

4 followers
About
Posts

Post has attachment
Spring Bank is engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. Learn more: http://bit.ly/2mjTsAA
Animated Photo
Add a comment...

Post has attachment
Have you seen our video about inarigivir's (formerly referred to as SB 9200) unique method of action? Watch it here:
Add a comment...

Post has attachment
Martin J. Driscoll, chairman, president, and chief executive officer of Spring Bank, and Nezam H. Afdhal, MD, chief medical officer of Spring Bank, will present at the upcoming Piper Jaffray 29th Annual Healthcare Conference on November 29 at 9:50am.
Add a comment...

Post has attachment
Babies born to a mother with hepatitis B have a greater than 90% chance of developing chronic hepatitis B if they are not properly treated at birth. Learn more from Hepatitis B Foundation:
Add a comment...

Post has attachment
Our CEO, Martin Driscoll, comments on Spring Bank's recent corporate and clinical developments. For the full release visit:
Add a comment...

Post has attachment
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
Add a comment...

Post has attachment
Learn more about the results from the first cohort of our inarigivir (formerly referred to as SB 9200) ACHIEVE Ph 2 trial from our recent presentation at AASLD's The Liver Meeting®. http://bit.ly/2yRll88
Photo
Add a comment...

Post has attachment

Post has attachment
Inarigivir's (formerly referred to as SB 9200) dual anti-viral mechanisms are designed to promote viral clearance and inhibit viral replication. Learn more about inarigivir's potential to treat hepatitis B:
Add a comment...

Post has attachment
Inarigivir (formerly referred to as SB 9200) is Spring Bank's most advanced Small Molecule Nucleic Acid Hybrids (SMNH) product candidate being developed for the treatment of chronic hepatitis B. Learn more in our video:
Add a comment...
Wait while more posts are being loaded